Enrich by linker type, without touching the target epitope
Enrichment is optional; when it is required, the choice of route directly affects recovery and the feasibility of downstream detection.
After transduction, CAR+ and CAR⁻ cells coexist in the population. For downstream killing or cytokine-release assays, negative cells dilute the effector signal; if only transduction efficiency is being assessed, measuring positivity is sufficient. This page addresses two questions: whether enrichment is needed, and which route to use.
Three anti-tag routes (G4S / Whitlow 218 / VHH) × two formats (direct nanobeads, indirect isolation kits). The recognition principle is the same as for detection antibodies, so detection and enrichment should follow the same linker route.
CAR+ Cell Enrichment Nanobeads (direct method)
| Cat No | Product Name | Details |
|---|---|---|
| GMLS-Tag003-Ab01-nanoIMB | SOLIDEX®-ISOEx Anti-G4S Linker Nanobeads (Column-Based) | Details |
| GMLS-Tag006-Ab01-nanoIMB | SOLIDEX®-ISOEx Anti-Whitlow (218) Linker Nanobeads (Column-Based) | Details |
| GMLS-Tag002-Ab01-nanoIMB | SOLIDEX®-ISOEx Anti-VHH Nanobeads (Column-Based) | Details |
Indirect CAR+ Cell Isolation Kits (indirect method)
| Cat No | Product Name | Details |
|---|---|---|
| GMLS-Tag003-Ab01-kit | SOLIDEX®-ISOEx Indirect Anti-G4S Linker Isolation Kit (Column-based) | Details |
| GMLS-Tag003-Ab01-kit-CF | SOLIDEX®-ISOEx Indirect Anti-G4S Linker Isolation Kit (Column-free) | Details |
| GMLS-Tag006-Ab01-kit | SOLIDEX®-ISOEx Indirect Anti-Whitlow (218) Isolation Kit (Column-based) | Details |
| GMLS-Tag006-Ab01-kit-CF | SOLIDEX®-ISOEx Indirect Anti-Whitlow (218) Isolation Kit (Column-free) | Details |
| GMLS-Tag002-Ab01-kit | SOLIDEX®-ISOEx Indirect Anti-VHH Isolation Kit (Column-based) | Details |
| GMLS-Tag002-Ab01-kit-CF | SOLIDEX®-ISOEx Indirect Anti-VHH Isolation Kit (Column-free) | Details |
SOLIDEX®-ISOEx Untouched negative selection covers Pan-T, CD4+ T, CD8+ T, NK and Classical Monocyte, each in Column-based and Column-free formats. After negative selection the target cells carry no antibody on their surface, so subsequent CAR transduction and phenotyping are unaffected.
| Cat No | Product Name | Details |
|---|---|---|
| GM-Pan-T-Cell-iso-kit | SOLIDEX®-ISOEx Untouched Human Pan-T Cell Isolation Kit (Column-based) | Details |
| GM-Pan-T-Cell-iso-kit-CF | SOLIDEX®-ISOEx Untouched Human Pan-T Cell Isolation Kit (Column-free) | Details |
| GM-CD4-T-Cell-iso-kit | SOLIDEX®-ISOEx Untouched Human CD4+ T Cell Isolation Kit (Column-based) | Details |
| GM-CD4-T-Cell-iso-kit-CF | SOLIDEX®-ISOEx Untouched Human CD4+ T Cell Isolation Kit (Column-free) | Details |
| GM-CD8-T-Cell-iso-kit | SOLIDEX®-ISOEx Untouched Human CD8+ T Cell Isolation Kit (Column-based) | Details |
| GM-CD8-T-Cell-iso-kit-CF | SOLIDEX®-ISOEx Untouched Human CD8+ T Cell Isolation Kit (Column-free) | Details |
| GM-NK-Cell-iso-kit | SOLIDEX®-ISOEx Untouched Human NK Cell Isolation Kit (Column-based) | Details |
| GM-NK-Cell-iso-kit-CF | SOLIDEX®-ISOEx Untouched Human NK Cell Isolation Kit (Column-free) | Details |
| GM-Tg-hg-T23212-iso-kit-1 | SOLIDEX®-ISOEx Untouched Human Classical Monocyte Isolation Kit (Column-based) | Details |
| GM-Tg-hg-T23212-iso-kit-CF-1 | SOLIDEX®-ISOEx Untouched Human Classical Monocyte Isolation Kit (Column-free) | Details |
Support for culture and detection after enrichment: recombinant cytokines, plus the flow cytometry antibodies, cytokine ELISAs and Anti-TAA antibodies described on the CAR Detection & Characterization page.
Recombinant Cytokines
| Cat No | Product Name | Details |
|---|---|---|
| GM-Tg-hg-T61698-Ag | Human IL-2/IL2 recombinant protein | Details |
| GM-Tg-hg-T35232-Ag | Human IL-7/IL7 recombinant protein | Details |
| GM-Tg-hg-T32240-Ag | Human IL-15/IL15 recombinant protein | Details |
| GM-Tg-hg-T51223-Ag | Human IL-21/IL21 recombinant protein | Details |
| GM-Tg-hg-T06671-Ag | Human IL-18/IL18 recombinant protein | Details |
| GM-Tg-hg-T13251-Ag | Human IL-12/IL12A recombinant protein | Details |
Grouped by cell type: T Cell-Associated = IL-2 / IL-7 / IL-15 / IL-21; NK Cell-Associated = IL-2 / IL-15 / IL-18; T / NK Cell-Associated (Potentiating) = IL-12 / IL-18.
| Enrichment needed | Enrichment not needed |
|---|---|
| Downstream functional assays (killing, cytokine release) require a defined effector population | Only transduction efficiency is assessed; CAR% is sufficient |
| CAR positivity is low and the signal would be diluted by negative cells | Positivity already meets the experimental requirement |
| Parallel CAR+ and CAR⁻ controls are required | Sample size is small and cannot absorb sorting loss |
| A phenotypically defined batch is needed for cryopreservation | Cell number itself is the limiting factor |
Important note: enrichment is not a required step in all CAR studies. Whether it is needed depends on the research question, CAR positivity, downstream assay design and the target cell population required.
| Direct nanobead method | Indirect nanobead method | |
|---|---|---|
| Recognition | Anti-tag nanobeads bind the CAR structure directly | Biotinylated anti-tag antibody + anti-biotin nanobeads |
| Labelling steps | One | Two |
| Products | Anti-G4S / Anti-Whitlow (218) / Anti-VHH Nanobeads | SOLIDEX®-ISOEx Indirect Anti-… Isolation Kit |
| Separation format | Column-based | Column-based / Column-free |
| Epitope occupancy | Beads occupy part of the epitope; a different antibody is recommended for subsequent detection | The antibody occupies the epitope, which can be avoided by selecting a different clone |
| Suitable for | Routine enrichment with fewer steps | Bead labelling interferes with downstream detection, or the recognition antibody must be changed |
Route 1 (direct): ① select the anti-tag nanobeads matching the CAR construct → ② beads bind the CAR structure → ③ magnetic separation → ④ collect the CAR+ population
Route 2 (indirect): ① biotinylated anti-tag antibody binds the CAR → ② add anti-biotin nanobeads → ③ magnetic separation → ④ collect the CAR+ population
| Step | Stage | Description |
|---|---|---|
| Step 1 | Starting Cells | PBMC or another starting sample within the product's intended use |
| Step 2 | Immune Cell Isolation | Isolate the target T / NK cells (untouched; target cells carry no antibody) |
| Step 3 | CAR Engineering | Lentiviral transduction |
| Step 4 | CAR+ Cell Enrichment (optional) | Choose the direct or indirect route according to the construct |
| Step 5 | CAR Expression & Phenotyping | Detect with an antibody against an unoccupied epitope |
1How do I choose between the direct and indirect method?
Fewer steps: direct. If subsequent detection must avoid bead masking, or the recognition antibody must be changed, use indirect.
2What is the difference between Column-based and Column-free?
Column-based usually gives higher purity but takes longer; Column-free usually gives higher recovery and is faster to perform.
3Is the CAR epitope occupied after enrichment?
With the direct method yes; use a different epitope for subsequent detection. With the indirect method this can be avoided by changing the antibody clone.
4Do target cells carry antibody after untouched isolation?
No. Negative selection labels only non-target cells; target cells remain untouched.
5How much cell loss does enrichment cause?
It depends on starting cell number, CAR positivity and separation format; run a small-scale test separation before scaling up.
6Do the beads need to be released?
Depends on the downstream assay; refer to the corresponding product protocol if release is required.